By Mill Chart
Last update: Dec 19, 2023
Take a closer look at JOHNSON & JOHNSON (NYSE:JNJ), a stock of interest to dividend investors uncovered by our stock screener. NYSE:JNJ excels in fundamentals and provides a decent dividend, all while maintaining a reasonable valuation. Let's break it down further.
ChartMill employs its own Dividend Rating system for all stocks. This score, on a scale of 0 to 10, is determined by evaluating different dividend factors, such as yield, historical performance, dividend growth, and sustainability. NYSE:JNJ has been assigned a 7 for dividend:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NYSE:JNJ has earned a 7 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NYSE:JNJ has achieved a 9:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
Our latest full fundamental report of JNJ contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
JOHNSON & JOHNSON
NYSE:JNJ (4/23/2024, 7:08:20 PM)
After market: 149.2 -0.36 (-0.24%)149.56
+0.44 (+0.3%)
These stocks are underwater right now and likely to remain so as the companies behind them manage serious problems.
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Stocks like KB Home (KBH), Interactive Brokers Group, Inc. (IBKR), QUALCOMM Incorporated (QCOM) and Johnson & Johnson (JNJ) recently hiked dividends.
Here are three dividend stocks to buy now offering stability, growth, and lifelong income in the pharmaceutical and tobacco industries.
These dividend stocks have proved time and again why they're the cream of the crop and will rise to the top once more.
We may not be headed to a full-blown crisis, but savvy investors should protect their portfolios now with these crash-proof stocks.
Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization. Pfizer acquired Seagen in 2023 while Merck bought Harpoon Therapeutics. So, here are some of the top biotech stocks to […]
Johnson & Johnson and Kenvue Inc. were ordered to pay $45 million to the family of an Illinois woman who blamed the companies’ baby powders for giving her a fatal cancer in what was the first verdict against the J&J spinoff in a decade-long litigation over the product.
As uncertainty in the global economy and geopolitical climate abounds, investors should focus on stocks with proven track records.
Friday’s ruling in Illinois came a day after a judge in Florida rejected similar claims.